Exchange: NASDAQ·Updated 06:59 PM EDT
APRE logo

APREAprea Therapeutics Inc

$0.6704
$0.0195
(2.83%)
Today
Closed $0.7095
$0.0391
(5.51%)
After Hours
Mkt Cap$8.54M
Vol74,703.00

About

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The Company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
8

Frequently Asked Questions

What is Market Cap of Aprea Therapeutics Inc?
What is the 52-week high for Aprea Therapeutics Inc?
What is the 52-week low for Aprea Therapeutics Inc?
What is Aprea Therapeutics Inc stock price today?
What was Aprea Therapeutics Inc stock price yesterday?
What is the PE ratio of Aprea Therapeutics Inc?
What is the Price-to-Book ratio of Aprea Therapeutics Inc?
What is the 50-day moving average of Aprea Therapeutics Inc?
How many employees does Aprea Therapeutics Inc have?

Advertisement|Remove ads.